This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.
Identification of novel biomarkers is needed to improve the diagnosis and prognosis of cardiomyopathy. Also,the marked variation of genes which is still unclear, may influence clinical outcomes is determined in part by genetic heterogeneity of the systemic response to pathological process. Specific aim: 1. Proteomics, microRNA-seq and metabolomics will be to determine the correlation of echocardiographic parameters of systolic and diastolic functional entry with circulating molecules 2. Genomics will be to determine the association of clinical outcome
Study Type
OBSERVATIONAL
Enrollment
2,000
Beijing Institute of heart, lung and blood vessel diseases
Beijing, Beijing Municipality, China
RECRUITINGBeijing Institute of heart, lung and blood vessel diseases
Beijing, Beijing Municipality, China
RECRUITINGShijie You
Beijing, China
ENROLLING_BY_INVITATIONThe primary objective of this study is to determine whether variation in genetic background or differentially expressed molecules influences clinical outcomes in cardiomyopathy.
The primary objective of this study is to determine whether variation in genetic background or molecules influences clinical outcomes in cardiomyopathy. Differentially expressed molecules are reported in multi-omics.
Time frame: Five year
Age for each participant
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
gender for each participant
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
Height for each participant
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
Weight for each participant
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
Past medical history for each participant including disease history, surgical history, and family
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
Life style for each participant including smoking history and drinking, specify how many years
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
blood lipids(LDL,HDL,VLDL)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
creatine
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
urea
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
blood glucose
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
D-dimer
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
hsCRP
Time frame: These data is collected from the cases' medical record in an average of 1 month after the sample recruiting
All-cause death
The data is collected during follow-up visit at 1/3/5 years after discharge
Time frame: One year/Three year/Five year
Re-hospitalization
Patients are hospitalized due to heart failure with decreasing left ventricular ejection fraction or worsen symptoms. The data is collected during follow-up visit at 1/3/5 years after discharge
Time frame: One year/Three year/Five year
Heart transplantation
Patients are underwent heart transplantation due to "pump failure of heart".The data is collected during follow-up visit at 1/3 years after discharge
Time frame: One year/Three year/Five year
Malignant arrythmia
Ventricular flutter and fibrillation, atrioventricular block,atrial fibrillation or other cardiac arrhythmia leads to syncope or should be Implantable Cardioverter-Defibrillator (ICD) implantation.
Time frame: One year/Three year/Five year
Worsening heart failure
Worsen heart failure is defined as decreased ejection fraction(left ventricular ejection fraction decreased over 10%), left ventricular ejection fraction \<45% and enlarged heart size measured by echocardiography and changing level of New York Heart Association (NYHA) Functional Classification.And patients who undergo left ventricular assist device (LVAD) will also be included.The data is collected during follow-up visit at 3/6/9/12/36/60 months after enrollment.
Time frame: One year/Three year/Five year
RNA/micro RNA/long-noncoding RNA-sequencing data
Time frame: The data is collected from lab in an average of 6 month after the sample recruiting
Proteomics on Liquid Chromatograph Mass Spectrometer/Mass Spectrometer of plasma sample
Time frame: The data is collected from lab in an average of 6 month after the sample recruiting
Exon sequencing data
Time frame: The data is collected from lab in an average of 6 month after the sample recruiting
Result of echocardiography-Ejection Fraction
The whole results of echocardiography report will be recorded. The indicate can reflect cardiac contraction function and be used for discriminating heart failure or non-heart failure as a main factor.
Time frame: Three year
Result of echocardiography-Left Ventricular End Diastolic Diameter
The whole results of echocardiography report will be recorded. The indicate can reflect the size of heart and be used for determination of heart enlargement.
Time frame: Three year
Result of echocardiography-E/A Ratio
The whole results of echocardiography report will be recorded. The indicate can reflect diastolic function.
Time frame: Three year